C4 Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-23.6M | $-25.1M | $-20.5M | $-32.2M | $-26.0M | $-26.3M | $-34.6M | $-24.7M |
| Depreciation & Amortization | $292.0K | $404.0K | $428.0K | $460.0K | $615.0K | $456.0K | $480.0K | $442.0K |
| Depreciation | $336.0K | $360.0K | $377.0K | $384.0K | $416.0K | $364.0K | $437.0K | $365.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $3.0M | $2.7M | $4.0M | $4.6M | $5.0M | $5.5M | $8.2M | $8.8M |
| Net Cash from Operating Activities | $-1.6M | $-29.9M | $-22.1M | $-31.2M | $-12.1M | $-33.3M | $-17.9M | $-24.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $37.0K | $64.0K | $11.0K | $411.0K | $185.0K | $0 | $-4.0K | $-13.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-14.8M | $16.2M | $-80.7M | $4.1M | $38.9M | $29.1M | $13.7M | $162.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $0 | $200.0K | $14.0K | $24.0K | $0 | $155.0K | $0 | $85.0K |
| Net Cash from Financing Activities | $33.7M | $462.0K | $118.7M | $7.8M | $0 | $-46.0K | $112.0K | $10.5M |
| Net Change in Cash | $17.3M | $-13.3M | $15.8M | $-19.3M | $26.9M | $-4.2M | $-4.2M | $-13.5M |
| Free Cash Flow | $-1.6M | $-30.0M | $-22.2M | $-31.6M | $-12.2M | $-33.3M | $-17.9M | $-24.1M |